CDRH Staff Cuts Focus On Administrative Workers, Spare Reviewers

One CDRH employee said the cuts already are having a major effect on morale.

Scissors cutting line of blocks with human icons; staff cuts concept.
About 200 CDRH staff were among the 3,500 FDA employees laid off on 1 April. (Cagkan Sayin/Shutterstock)
Key Takeaways
  • Cuts at CDER included employees in consumer education, meeting logistics, communications and employee management.
  • Two CDRH employees who remained at the FDA said staff morale is down and they cannot focus on their work.
  • Another staffer said most Americans would not stand for the way FDA employees had been treated if they knew the full story.

Employees in offices dealing with industry and consumer education, meeting logistics, communications and employee management at the US Food and Drug Administration’s Center for Devices and Radiological Health were among...

Most if not all employees were cut in the Office of Communication, Information Disclosure, Training and Education, which develops device safety alerts, as well as educates the public about the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

US FDA Punts On New COVID-19 Framework’s Impact On Fall Shots

 

The FDA’s advisors split on whether to update COVID-19 vaccines for the fall. The agency refused to discuss the impact of the new vaccine framework on availability.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

More from Agency Leadership

UK MHRA’s Clinical Trial Lead On Combined Reviews, The Notification Scheme & Increasing Diversity

 

In light of the UK’s MHRA announcing a major overhaul of its clinical trial legislation, the agency’s deputy director for clinical investigations and trials Andrea Manfrin tells the Pink Sheet what sponsors can expect from the new regulation.

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.